drugset

drugset / Trial / NCT03985007

CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT03985007 ↗

Phase 2 Completed 40 enrolled The First Affiliated Hospital of Soochow University Jining Medical University · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia

Timeline

Start: 2018-01-01
Primary completion: 2020-12-31
Completion: 2021-03-16

Publications

Yin J, Wan CL, Zhang L, Zhang H, Bai L, Zhou HX, Xu MZ, Chen LY, Qian CS, Qiu HY, Chen SN, Tang XW, Wu DP, Zhang YM, Sun AN, Xue SL. A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2021 Sep 3;11:726926. doi: 10.3389/fonc.2021.726926. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cytarabine	Small molecule	10 mg/m2	Subcutaneous
Subject	Decitabine	Small molecule	20 mg/m2	Intravenous
Subject	Granulocyte colony-stimulating factor	Protein / enzyme biologic	200 mg/m2	Subcutaneous
Subject	Idarubicin	Small molecule	5 mg	Intravenous
Subject	Tucidinostat	Small molecule	30 mg	Oral

Indications